By loading a chelation drug into a nano-sized homing device, researchers at Clemson University have reversed in an animal model the deadliest effects of chronic kidney disease, which kills more people in the United States each year than breast or prostate cancer. When kidneys stop working properly, calcium builds up in artery tissue, leading to heart disease. Although nearly half a million Americans receive kidney dialysis, heart disease is the leading cause of death for people with chronic kidney disease.

Human kidney cross section on scientific background
“The findings are very exciting scientifically, but also for the thousands of patients who could potentially benefit from this technology one day,” said Naren Vyavahare, professor of bioengineering at Clemson and the principal investigator of the research.
Chelation, a method of removing metals such as iron and lead from the body, has been used experimentally for some people with heart disease. The therapy is not approved by the Food and Drug Administration, but the National Institutes of Health has sponsored two large-scale, multi-center studies using ethylene diamine tetra-acetic acid, or EDTA, as chelation therapy for people with heart disease.
In clinical studies, EDTA is included in an infusion that circulates through the body; it’s systemic and non-specific. This method of chelation has shown good results in improving heart function, especially in diabetic patients, Vyavahare said. But EDTA infusion therapy is arduous (it requires 40 infusions over a period of a year), and it can cause side effects, including a depletion of calcium from the blood and from bone.
Now, in a paper published in Scientific Reports, a Nature publication, Vyavahare’s team describes how they developed an animal model that mimics a human’s chronic kidney disease. Animals were treated either with EDTA infusions, like in the NIH human trials, or with EDTA enclosed in a nanoparticle coupled with an antibody that seeks out damaged elastin. In animals that received the targeted therapy, calcium buildup was destroyed, without causing side effects, better than with EDTA infusions alone. Moreover, the calcification did not come back up to four weeks after the last injection, even though other signs of chronic kidney disease were present.
Source: http://newsstand.clemson.edu/
Recent Comments